Dayvigo Logo

1-866-4DAYVIGO (1-866-432-9844)

Monday – Friday, 9 am to 8 pm ET

Patient Support

DAYVIGO™ Together

Patients have unique needs when it comes to living with insomnia. DAYVIGO Together is a support program for patients living with the challenges that come with poor sleep. Patients can sign up to get access to tools and educational resources to help them navigate their personal insomnia challenges by calling 1-866-4DAYVIGO or visiting

DAYVIGO Instant Savings Card Program*

Eligible commercially insured patients may pay as little as $30 of out-of-pocket expenses. Instant Savings Card benefit is limited to twelve uses annually.

Commercially insured patients could have additional financial responsibility for any amounts over Eisai's maximum liability.

Who's Eligible for Savings?

This offer is available to commercially insured patients. This offer is not available to patients enrolled in a state or federal healthcare program, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE. If you have any questions regarding eligibility, call the DAYVIGO Assistance Program at 1-866-4DAYVIGO (1-866-432-9844).

Register Online to Activate Savings

To receive an Instant Savings Card, patient must register for the program. Please click here to register online, or call The DAYVIGO Assistance Program at 1-866-4DAYVIGO (1-866-432-9844) to register.

*Eligibility Criteria

  • Good toward the purchase of DAYVIGO prescriptions
  • Eligible commercially insured patients may pay as little as $30 of out-of-pocket expenses
  • Instant Savings Card benefit is limited to up to twelve uses annually
  • Commercially insured patients could have additional financial responsibility for any amounts over Eisai’s maximum liability
  • No substitutions permitted
  • Save the Instant Savings Card to reuse with each prescription
  • Not available to patients enrolled in Federal or state healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE
  • Patients must have commercial insurance
  • Cash paying patients are excluded
  • Not valid for prescriptions for DAYVIGO or any other product reimbursed in full by third-party payers
  • May not be combined with any other discount or offer
  • Federal law prohibits the selling, purchasing, trading, or counterfeiting of this card
  • Void outside the USA and where prohibited by law
  • Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
  • You must be 18 years or older to use the card
  • Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the card and complying with any other conditions imposed by insurance carriers, third-party payers, and applicable law on the redemption
  • The value of this card is not contingent on any prior or future purchases
  • This card may not be accepted at all pharmacies
  • This card is not an insurance program
  • No membership fees
  • This offer will expire 12/31/2021

DAYVIGO Patient Assistance Program

Eisai has created the DAYVIGO Patient Assistance Program for eligible patients who may need assistance paying for DAYVIGO. This program provides DAYVIGO at no cost to financially needy patients who meet program eligibility criteria.

Healthcare providers can call the DAYVIGO Patient Assistance Program at 866-349-3026. Hours of operation are Monday to Friday 8 am to 8 pm ET.

Eisai reserves the right, at its sole discretion, to discontinue the Patient Assistance Program or change the qualifications at any time. All patient information remains confidential. Product supply for the program depends upon availability.

Fax: 844-737-3493

Electronic Prior Authorization (ePA)

Eisai subscribes to CoverMyMeds. CoverMyMeds is an online platform through which prescribers and pharmacies can submit electronic prior authorization forms.

For more information, please visit CoverMyMeds at or call 866-452-5017.

Need Coding Information For DAYVIGO™?

Find NDC codes specific to DAYVIGO
Dayvigo Panel Image

How Does DAYVIGO™ Work?

Visit to learn more

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

+ Expand - Collapse


DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.



  • DAYVIGO is contraindicated in patients with narcolepsy.


  • Central Nervous System (CNS) Depressant Effects and Daytime Impairment:

    DAYVIGO can impair daytime wakefulness. CNS depressant effects may persist in some patients up to several days after discontinuing DAYVIGO. Prescribers should advise patients about the potential for next-day somnolence.

    Driving ability was impaired in some subjects taking DAYVIGO 10 mg. Risk of daytime impairment is increased if DAYVIGO is taken with less than a full night of sleep remaining or at a higher than recommended dose. If taken in these circumstances, patients should not drive or engage in activities requiring mental alertness.

    Use with other classes of CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of DAYVIGO and concomitant CNS depressants may be necessary when administered together. Use of DAYVIGO with other insomnia drugs is not recommended. Patients should be advised not to consume alcohol in combination with DAYVIGO.

    Because DAYVIGO can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls.

  • Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-Like Symptoms:

    Sleep paralysis, an inability to move or speak for up to several minutes during sleep-wake transitions, hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions can occur with DAYVIGO. Prescribers should explain these events to patients.

    Symptoms similar to mild cataplexy can occur with DAYVIGO and can include periods of leg weakness lasting from seconds to a few minutes, can occur either at night or during the day, and may not be associated with identified triggering event (e.g., laughter or surprise).

  • Complex Sleep Behaviors:

    Complex sleep behaviors, including sleep-walking, sleep-driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), have been reported to occur with the use of hypnotics such as DAYVIGO. Events can occur in hypnotic-naïve and hypnotic-experienced persons. Patients usually do not remember these events. Complex sleep behaviors may occur following the first or any subsequent use of DAYVIGO, with or without the concomitant use of alcohol and other CNS depressants. Discontinue DAYVIGO immediately if a patient experiences a complex sleep behavior.

  • Patients with Compromised Respiratory Function:

    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function. DAYVIGO has not been studied in patients with moderate to severe obstructive sleep apnea (OSA) or chronic obstructive pulmonary disease (COPD).

  • Worsening of Depression/Suicidal Ideation:

    Incidence of suicidal ideation or suicidal behavior, as assessed by questionnaire, was higher in patients receiving DAYVIGO than placebo (0.3% for DAYVIGO 10 mg, 0.4% for DAYVIGO 5 mg, and 0.2% for placebo). In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions (including completed suicides) have been reported. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed at any one time. The emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

  • Need to Evaluate for Comorbid Diagnoses:

    Treatment of insomnia should be initiated only after careful evaluation of the patient. Re-evaluate for comorbid conditions if insomnia persists or worsens after 7 to 10 days of treatment. Worsening of insomnia or the emergence of new cognitive or behavioral abnormalities may be the result of an unrecognized underlying psychiatric or medical disorder and can emerge during the course of treatment with sleeppromoting drugs such as DAYVIGO.


  • The most common adverse reaction (reported in 5% of patients treated with DAYVIGO and at least twice the rate of placebo) with DAYVIGO was somnolence (10% for DAYVIGO 10 mg, 7% for DAYVIGO 5 mg, 1% for placebo).


  • CYP3A Inhibitors: The maximum recommended dose of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors. Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors.

  • CYP3A Inducers: Avoid concomitant use of DAYVIGO with moderate or strong CYP3A inducers.


  • Pregnancy and Lactation: There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to DAYVIGO during pregnancy. Healthcare providers are encouraged to register patients in the DAYVIGO pregnancy registry by calling 1-888-274-2378. There are no available data on DAYVIGO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

    There are no data on the presence of lemborexant in human milk, the effects on the breastfed infant, or the effects on milk production. Infants exposed to DAYVIGO through breastmilk should be monitored for excess sedation.

  • Geriatric Use: Exercise caution when using doses higher than 5 mg in patients ≥65 years old.

  • Renal Impairment: Patients with severe renal impairment may experience an increased risk of somnolence.

  • Hepatic Impairment: The maximum recommended dose of DAYVIGO is 5 mg in patients with moderate hepatic impairment. DAYVIGO is not recommended in patients with severe hepatic impairment. Patients with mild hepatic impairment may experience an increased risk of somnolence.


  • DAYVIGO is a Schedule IV-controlled substance.

  • Because individuals with a history of abuse or addiction to alcohol or other drugs may be at increased risk for abuse and addiction to DAYVIGO, follow such patients carefully.

For more information about DAYVIGO, see full Prescribing Information.

This information is intended for use by healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.

DAYVIGO™ is a trademark of Eisai R&D Management Co., Ltd. and is licensed to Eisai Inc.©2020 Eisai Inc.